UK Undervalued Screen: Top 5 — November 14, 2026
Today's top 5 undervalued UK names
Ranked by ValQ's quantum-weighted valuation upside, run fresh against current prices.
| # | Ticker | Upside | Market Cap |
|---|---|---|---|
| 1 | BP.L | +55.5% | $89B |
| 2 | SHEL.L | +53.1% | $211B |
| 3 | AZN.L | +36.4% | $217B |
| 4 | GSK.L | +34.7% | $77B |
| 5 | HSBA.L | +24.5% | $232B |
Methodology
Each name is independently valued using ValQ's blended multi-method approach -- DCF, trading multiples, and comparable analysis -- then ranked by the gap between that valuation and the current market price. This is not a recommendation to buy; it's a transparent, repeatable screen anyone can re-run.
Run this screen yourself, or check any individual ticker in the UK market.